Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
Phase 1/Phase 2
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
Inclusion Criteria:
- De novo multiple myeloma
- ECOG 0-2
- No serious co-morbid illnesses and adequate organ function
- > 4 weeks from systemic steroids
Exclusion Criteria:
- No existing secondary malignancies and no history of secondary malignancies in the
past 5 years
- No active autoimmune disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Multiple myeloma
Authority:
United States: Food and Drug Administration
Study ID:
K-0007
NCT ID:
NCT00116441
Start Date:
October 2000
Completion Date:
October 2004
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Cancer
- PSCT
- Peripheral Stem Cell Transplant
- Chemotherapy
- GVAX
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|---|
| Johns Hopkins University | Baltimore, Maryland 21205 |
